Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for myeloma patients: drug combo aims to keep cancer at bay

NCT ID NCT07555938

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study tests whether adding the experimental drug cevostamab to standard medications (pomalidomide and dexamethasone) works better than current treatments for multiple myeloma. About 380 adults whose cancer came back after 1 to 3 prior therapies will take part. The goal is to see if the combination can make the cancer disappear completely or delay its return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

  • Auxilio Mutuo Cancer Center

    RECRUITING

    San Juan, 917, Puerto Rico

  • Chonnam National University Hwasun Hospital

    RECRUITING

    Jeollanam-do, 58128, South Korea

  • City of Hope - Lennar Foundation Cancer Center

    RECRUITING

    Irvine, California, 92618, United States

  • City of Hope National Medical Center

    RECRUITING

    Duarte, California, 91010-3012, United States

  • Emory University Hospital Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

  • Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists

    RECRUITING

    Winston-Salem, North Carolina, 27103, United States

  • Nagoya City University Hospital

    RECRUITING

    Aichi, 467-8602, Japan

  • Novant Health Cancer Institute

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • Seoul St Mary's Hospital

    RECRUITING

    Seoul, 06591, South Korea

  • The Cancer Institute Hospital of JFCR

    RECRUITING

    Tokyo, 135-8550, Japan

  • TriHealth Cancer and Blood Institute

    RECRUITING

    Cincinnati, Ohio, 45220, United States

  • University Hospital Kyoto Prefectural University of Medicine

    RECRUITING

    Kyoto, 602-8566, Japan

  • Yamagata University Hospital

    RECRUITING

    Yamagata, 990-9585, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.